| Title | Mechanisms of multidrug resistance (MDR) in cancer: an overview | |
| Author | Asterios S. Tsiftsoglou
Professor of Pharmacology, Dept, of Pharmaceutical Sciences, Aristotle University of Thessaloniki, Greece |
|
| Citation | Tsiftsoglou, A.S.: Mechanisms of multidrug resistance (MDR) in cancer: an overview, Epitheorese Klin. Farmakol. Farmakokinet. 12(3): 87-90 (1998) | |
| Publication Date | Received for publication: 20 October 1998
Accepted for publication: 25 October 1998 |
|
| Full Text Language | English | |
| Order – Buy | pharmakonpress[at]pharmakonpress[.]gr | |
| Keywords | Multidrug resistance, cancer, mechanisms. | |
| Other Terms | review article | |
| Introduction | Treatment of malignant tumors with conventional antineoplastic agents quite often leads to the development of drug resistance. This phenomenon is characterised by partial or complete failure of cytotoxic agents to counteract malignant growth. Drug-resistance occurs when drug-sensitive cancer cells undergo changes in their genetic make-up, metabolism and drug-transport processes. Much higher doses (100-1000 fold) of drugs are needed to prevent tumor growth in drug-resistant tumors. The development of resistance in tumors normally occurs in less than six months or even after longer treatment (1-2 years). […] | |
| References | 1. Riordan J.R., Ling V.: Pharmacol. Ther. 28: 51-75 (1985)
2. Beck W.T.: Biochem. Pharmacol. 30: 2879-2887 (1987) 3. Biedler J.: Cancer Res. 54: 666-678 (1994) 4. Gottesman M.M., Pastan I.: Ann. Rev. Biochem. 62: 385-427 (1993) 5. Nielsen D., Shovgaard T.: Biochem. Biophys. Acta 1139: 169-183 (1997) 6. Roepe P.D.: Biochim. Biophys. Acta Rev. Biomembr. 1241: 405 (1995) 7. Shimke R.T.: Cell 37: 705-713 (1984) 8. Roninson I.B.: Biochem. Pharmacol. 43: 95-102 (1992) 9. Ueda K., Cornwell M.M., Gottesman M.M., Pastan I., Roninson LB., Ling V., Riordan J.R.: BBRC 141: 956-962 (1986) 10. Gross P., Croop J., Housman D. Cell 47: 371-380 (1986) 11. Ueda K., Cardarelli C., Gottesman M.M., Pastan I.: Proc. Nati. Acad. Sel. USA 54: 3004-3008 (1987) 12. Simon S., Roy, Schindler M.: Proc. Natl. Acad. Sci. USA 91: 1128-1132 (1994) 13. Hickman J.A.: Apoptosis and chemotherapy resistance Eur. J. Cancer 32A: 921-926 (1996) 14. Milner J.: DNA damage, p53 and anticancer therapies Nat. medicine 1: 879-880 (1995) 15. Zunino F., Perego P., Pilotti S., Pratesi G., Supino R., Arcamone F.: Pharmacol. Ther. 76: 177-185 (1997) 16. Au J.L.S., Pauchal N., Li Dong, Gan Y.: Pharmaceutical Res 14: 1659-1671 (1997) 17. Ford J.M., Hait W.N.: Pharmacol. Rev. 42: 155-199 (1990) 18. Sikic B.I.: J. Clin. Oncol.: 1629-1635 (1993) 19. Teicher B.A.: Eur. J. of Cancer 30A: 1411-1413 (1994) 20. McLeod H.L.: Eur. J. Cancer 30A: 2039-2041 (1994) 21. Priebe W., Perez-Soler R.: Pharmac. Ther. 60: 215-234 (1993) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board